The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis
Metrics: PDF 2366 views | HTML 2341 views | ?
Jianting Long1,*, Shi Fang2,*, Qiangsheng Dai1, Xiaolian Liu3, Wanshou Zhu3, Shenming Wang4
1Department of Medicinal Oncology, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China
2Department of Clinic Nutrition, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China
3Department of Hematology, Gaozhou People’s Hospital, Gaozhou 525200, China
4Department of Vascular Surgery, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China
*These authors are co-first authors
Wanshou Zhu, email: [email protected]
Shenming Wang, email: [email protected]
Keywords: acute myeloid leukemia, Wilms’ tumor gene 1, association, meta-analysis
Received: November 18, 2015 Accepted: February 23, 2016 Published: March 16, 2016
Although a number of studies suggested that WT1 rs16754 polymorphism might be related to decreased relapse free survival (RFS) and overall survival (OS). The results remain controversial. Published reports were searched in PubMed, EMBASE, and Google Scholar. Twelve publications with 3903 patients had met the inclusion criteria and were subjected to further examination. We found WT1 rs16754 polymorphism was significantly associated with OS in AML (OR = 0.62; 95% CI 0.52 – 0.75; p < 0.00001; I2 = 47%). WT1 rs16754 polymorphism was also significantly associated with RFS in AML (OR = 0.69; 95% CI 0.57 – 0.83; p < 0.001; I2 = 46%). In the subgroup analyses of age, race, and subtype of AML, WT1 rs16754 polymorphism was a independent favorable-risk marker. In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML. It could be used as a cost-effective prognostic biomarker for AML.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.